---
title: "Ersodetug (RZ358) in Tumor hyperinsulinism: Expected outcomes of therapy"
description: "Formulary evidence on Ersodetug (RZ358) in Tumor hyperinsulinism: Expected outcomes of therapy. Topics: Ersodetug: primary endpoint and success threshold in upLIFT, preliminary; Ersodetug: additional outcomes measured in upLIFT; Ersodetug: outcomes in the peer-reviewed expanded access series; Ersodetug: manufacturer-described outcomes of expanded access use; 2 further topics. 6 evidence topics quoted from 7 sources."
canonical: "https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/product-information-and-disease-description/expected-outcomes-of-therapy"
published: "2026-11-15T20:24:18-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Ersodetug (RZ358) in Tumor hyperinsulinism: Expected outcomes of therapy

<a id="heading-2.2.2.7"></a>

## 2.2.2.7 Expected Outcomes of Therapy

<a id="topic-2.2.2.7-1"></a>

### Ersodetug: primary endpoint and success threshold in upLIFT, preliminary

> “The primary efficacy endpoint in the upLIFT study is the proportion of patients able to achieve at least a 50% reduction from baseline in glucose infusion rate (GIR), a measure of intravenous glucose dependency for underlying hypoglycemia.”
> “To achieve statistical significance for the endpoint, the lower bound of the 95% confidence interval for percent of patients responding must exceed 30%, which equates to at least 9 responders (≥56%), based on enrollment of 16 participants.”
> “To date, 13 participants have met the responder criterion, including 12 who also achieved a complete discontinuation of IV glucose.”
> “Results for the completed study, including statistical analysis of the primary endpoint, are expected by mid-December 2026.”

Source: [Rezolute upLIFT results release (2026)](https://ir.rezolutebio.com/news/detail/389/rezolute-announces-positive-results-from-the-phase-3-uplift-study-in-tumor-hyperinsulinism)

<a id="topic-2.2.2.7-2"></a>

### Ersodetug: additional outcomes measured in upLIFT

> “Additional endpoints include the number of participants achieving complete discontinuation of GIR and time to discontinuation, time to discharge from the hospital as applicable, extent of hypoglycemia events and hypoglycemia time in the outpatient setting by self-monitored blood glucose and continuous glucose monitor, respectively, and patient reported quality of life.”

Source: [Rezolute upLIFT results release (2026)](https://ir.rezolutebio.com/news/detail/389/rezolute-announces-positive-results-from-the-phase-3-uplift-study-in-tumor-hyperinsulinism)

<a id="topic-2.2.2.7-3"></a>

### Ersodetug: outcomes in the peer-reviewed expanded access series

> “Ersodetug therapy resulted in reduced hypoglycemia burden, ability to discontinue parenteral glucose infusion, allowing discharge from hospital, use of fewer antihypoglycemic therapies, and improved ECOG performance status in individuals with severe, refractory tumor HI.”
> “The median treatment duration with ersodetug (11.5 months, range 5-17) tended to correspond to patient lifespan in the setting of metastatic disease.”

Source: [Strosberg et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13671785/)

<a id="topic-2.2.2.7-4"></a>

### Ersodetug: manufacturer-described outcomes of expanded access use

> “In summary, 75% of the patients receiving IV dextrose/total parenteral nutrition”
> “in the EAP achieved a complete discontinuation of IV dextrose/TPN.”

Source: [Rezolute Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926123364/rzlt-20260930x10q.htm)

> “Discharge from inpatient to outpatient care”
> “Ability to resume regular daily activities (e.g., driving)”
> “Resumption of tumor-directed therapies”
> “Potential increase in survival, as hypoglycemia-stabilized patients get anti-tumor treatment”

Source: [Rezolute October corporate presentation (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926120205/tm2628517d1_ex99-1.htm)

<a id="topic-2.2.2.7-5"></a>

### Current multimodal therapy in metastatic insulinoma: hypoglycemia control and survival

> “The final cohort comprised 275 patients with individual-level data.”
> “The liver was the predominant metastatic site (89.5%), while 82.8% of patients (111/134 evaluable) required nutritional support, reflecting the profound endocrine and metabolic burden of the disease.”
> “A disease control rate of 69.9% (153 evaluable) was observed with multimodal therapy, and definitive hypoglycemia control was achieved in 62.1% (164/264) of patients at last follow-up.”
> “Median overall survival from the time of metastatic diagnosis was 84 months (95% CI: 61.8-111), with a subset of patients surviving beyond 25 years.”

Source: [Guerrero-Pérez et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/43000590/)

> “Clinical data on 14 patients with metastatic insulinoma (metastases to the liver, skeleton, and lung) were reviewed in this descriptive study.”
> “The time of the 7 deaths ranged from 2.5 to 10.4 years (median time to death was 8.2 years).”
> “This compares to previous reports of median survival of about 2 years.”
> “Hypoglycemia was well-controlled and did not cause the deaths.”

Source: [Masharani et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11954510/)

<a id="topic-2.2.2.7-6"></a>

### Current therapy in NICTH: recovery and mortality

> “Outcomes were available for 223 cases, and the overall recovery rate among all the participants was 77% (n = 172).”
> “Surgical removal was the most common treatment modality employed in 110 (47.2%) cases.”
> “In light of a high mortality rate, approximating 23%, identifying and comprehensively evaluating prognostic factors is paramount and necessitate further investigative efforts.”

Source: [Ata et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10897872/)

## Related pages
- [Ersodetug (RZ358): Tumor hyperinsulinism](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: Terms and abbreviations](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/terms-and-abbreviations.md)
- [Ersodetug (RZ358): Tumor hyperinsulinism](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/executive-summary) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/executive-summary.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: Product information and disease description](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/product-information-and-disease-description.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: Clinical evidence](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/clinical-evidence.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: Economic information and modeling report](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/economics) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/economics.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: References](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/references) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/references.md)
